NeuroThera Labs Launches Phase IIb Trial for Tourette Syndrome Treatment in Germany
July 15, 2026 — NeuroThera Labs initiates Phase IIb trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School in Germany. The study builds on promising Phase IIa results showing 21% tic reduction.